Literature DB >> 33377103

A protocol for displaying viral envelope glycoproteins on the surface of vesicular stomatitis viruses.

Touraj Aligholipour Farzani1, Angela Chov1, Alon Herschhorn1,2,3,4.   

Abstract

We describe the production of single-cycle (sc) and replication-competent recombinant vesicular stomatitis viruses (rcVSVs) displaying heterologous envelope glycoproteins (Envs) on their surface. We prepare scVSVs by transiently expressing HIV-1 Envs or SARS-CoV-2 spike followed by infection of the cells with scVSV particles, which do not carry the vsv-g gene. To prepare rcVSVs, we replace the vsv-g with a specific env-encoding gene, transfect cells with multiple plasmids for production of the genomic RNA and viral proteins, and rescue replication-competent viruses.
© 2020 The Author(s).

Entities:  

Keywords:  Cell culture; Cell-based assays; Immunology; Molecular biology

Mesh:

Substances:

Year:  2020        PMID: 33377103      PMCID: PMC7757661          DOI: 10.1016/j.xpro.2020.100209

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


  26 in total

1.  In vivo delivery of cytoplasmic RNA virus-derived miRNAs.

Authors:  Ryan A Langlois; Jillian S Shapiro; Alissa M Pham; Benjamin R tenOever
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

2.  Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity.

Authors:  Miranda Harris; Sneha Ratnapriya; Angela Chov; Héctor Cervera; Alisha Block; Christopher Gu; Nathaniel Talledge; Louis M Mansky; Joseph Sodroski; Alon Herschhorn
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

3.  An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors.

Authors:  Alon Herschhorn; Andres Finzi; David M Jones; Joel R Courter; Akihiro Sugawara; Amos B Smith; Joseph G Sodroski
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

4.  Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

Authors:  Marie Pancera; Tongqing Zhou; Aliaksandr Druz; Ivelin S Georgiev; Cinque Soto; Jason Gorman; Jinghe Huang; Priyamvada Acharya; Gwo-Yu Chuang; Gilad Ofek; Guillaume B E Stewart-Jones; Jonathan Stuckey; Robert T Bailer; M Gordon Joyce; Mark K Louder; Nancy Tumba; Yongping Yang; Baoshan Zhang; Myron S Cohen; Barton F Haynes; John R Mascola; Lynn Morris; James B Munro; Scott C Blanchard; Walther Mothes; Mark Connors; Peter D Kwong
Journal:  Nature       Date:  2014-10-08       Impact factor: 49.962

5.  Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120.

Authors:  Pengfei Jiang; Yanxia Liu; Xiaolei Yin; Fei Yuan; YuChun Nie; Min Luo; Zheng Aihua; Du Liyin; Mingxiao Ding; Hongkui Deng
Journal:  Biochem Biophys Res Commun       Date:  2005-11-21       Impact factor: 3.575

6.  A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry.

Authors:  Alon Herschhorn; Christopher Gu; Nicole Espy; Jonathan Richard; Andrés Finzi; Joseph G Sodroski
Journal:  Nat Chem Biol       Date:  2014-08-31       Impact factor: 15.040

7.  Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

Authors:  Alina Baum; Benjamin O Fulton; Elzbieta Wloga; Richard Copin; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Gurinder S Atwal; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

8.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

9.  Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.

Authors:  Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Lars Pache; Sebastian Burgstaller-Muehlbacher; Paul D De Jesus; Peter Teriete; Mitchell V Hull; Max W Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina M Herbert; Kuoyuan Cheng; Tu-Trinh H Nguyen; Andrey Rubanov; Yuan Pu; Courtney Nguyen; Angela Choi; Raveen Rathnasinghe; Michael Schotsaert; Lisa Miorin; Marion Dejosez; Thomas P Zwaka; Ko-Yung Sit; Luis Martinez-Sobrido; Wen-Chun Liu; Kris M White; Mackenzie E Chapman; Emma K Lendy; Richard J Glynne; Randy Albrecht; Eytan Ruppin; Andrew D Mesecar; Jeffrey R Johnson; Christopher Benner; Ren Sun; Peter G Schultz; Andrew I Su; Adolfo García-Sastre; Arnab K Chatterjee; Kwok-Yung Yuen; Sumit K Chanda
Journal:  Nature       Date:  2020-07-24       Impact factor: 69.504

10.  Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.

Authors:  Fabian Schmidt; Yiska Weisblum; Frauke Muecksch; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Julio C C Lorenzi; Pilar Mendoza; Magdalena Rutkowska; Eva Bednarski; Christian Gaebler; Marianna Agudelo; Alice Cho; Zijun Wang; Anna Gazumyan; Melissa Cipolla; Marina Caskey; Davide F Robbiani; Michel C Nussenzweig; Charles M Rice; Theodora Hatziioannou; Paul D Bieniasz
Journal:  J Exp Med       Date:  2020-11-02       Impact factor: 17.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.